Exagamglogene autotemcel

Therapeutic indications

Exagamglogene autotemcel is indicated for:

β-thalassemia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Exagamglogene autotemcel is indicated for the treatment of transfusion-dependent β-thalassemia (TDT) in patients 12 years of age and older for whom haematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen (HLA)-matched related HSC donor is not available.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Sickle cell disease

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Exagamglogene autotemcel is indicated for the treatment of severe sickle cell disease (SCD) in patients 12 years of age and older with recurrent vaso-occlusive crises (VOCs) for whom haematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen (HLA)-matched related HSC donor is not available.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Exagamglogene autotemcel is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Patients seropositive for human immunodeficiency virus, hepatitis B virus or hepatitis C virus

at least one of
Human immunodeficiency virus infection
Type B viral hepatitis
Viral hepatitis C

Blood, organ, tissue, and cell donation

at least one of
Blood unit collection
Organ retrieval operation
Transplantation

Hydroxycarbamide

Hydroxycarbamide

Voxelotor, crizanlizumab

at least one of
Voxelotor
Crizanlizumab

Iron chelators

at least one of
Deferoxamine
Deferiprone
Deferasirox

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2023: CASGEVY Suspension for infusion
Summary of Product Characteristics (SPC) 2024: CASGEVY Dispersion for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈